XTX Topco Ltd Acquires New Stake in BioNTech SE (NASDAQ:BNTX)

XTX Topco Ltd acquired a new stake in shares of BioNTech SE (NASDAQ:BNTX) in the third quarter, HoldingsChannel reports. The firm acquired 3,862 shares of the company’s stock, valued at approximately $459,000.

A number of other large investors also recently bought and sold shares of BNTX. Planning Capital Management Corp lifted its holdings in shares of BioNTech by 45,000.0% in the 3rd quarter. Planning Capital Management Corp now owns 451 shares of the company’s stock worth $54,000 after buying an additional 450 shares during the period. Blue Trust Inc. lifted its holdings in shares of BioNTech by 491.1% in the 3rd quarter. Blue Trust Inc. now owns 467 shares of the company’s stock worth $55,000 after buying an additional 388 shares during the period. GAMMA Investing LLC lifted its holdings in shares of BioNTech by 21.7% in the 3rd quarter. GAMMA Investing LLC now owns 623 shares of the company’s stock worth $74,000 after buying an additional 111 shares during the period. Clear Harbor Asset Management LLC purchased a new stake in shares of BioNTech in the 3rd quarter worth $210,000. Finally, Probity Advisors Inc. purchased a new stake in shares of BioNTech in the 3rd quarter worth $216,000. Hedge funds and other institutional investors own 15.52% of the company’s stock.

BioNTech Trading Down 0.3 %

Shares of NASDAQ:BNTX opened at $120.38 on Friday. The business’s 50-day moving average is $113.86 and its 200 day moving average is $100.38. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21. The firm has a market capitalization of $28.62 billion, a P/E ratio of -57.32 and a beta of 0.22. BioNTech SE has a 1 year low of $76.53 and a 1 year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings data on Monday, November 4th. The company reported $0.81 earnings per share for the quarter, beating analysts’ consensus estimates of ($1.26) by $2.07. The business had revenue of $1.24 billion for the quarter, compared to analyst estimates of $514.08 million. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The company’s revenue was up 38.9% on a year-over-year basis. During the same period in the prior year, the company earned $0.73 earnings per share. On average, research analysts predict that BioNTech SE will post -3.72 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the company. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and upped their target price for the stock from $90.00 to $137.00 in a report on Friday, November 8th. Wells Fargo & Company started coverage on BioNTech in a report on Wednesday. They issued an “overweight” rating and a $170.00 target price for the company. HC Wainwright restated a “buy” rating and set a $150.00 price objective on shares of BioNTech in a research note on Monday, November 18th. Bank of America upped their price objective on BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, JPMorgan Chase & Co. decreased their price objective on BioNTech from $124.00 to $122.00 and set a “neutral” rating for the company in a research note on Tuesday, November 26th. Four investment analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $140.76.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.